Diabetes-focused Poxel names Eli Lilly vet David Moller as CSO; Acceleron's CBO hops ship to lead startup
→ After passing their third straight Phase III trial for its new kind of diabetes tablet in Japan, French pharma Poxel has tapped David Moller as CSO. Moller has focused his career in the fields of diabetes and metabolic disorders. He most recently served as CSO at Sigilon Therapeutics and has previously completed stints at Eli Lilly, as VP of endocrine and cardiovascular research and clinical investigation, and Merck, as VP of metabolic disorders. With his new role, Moller will be based in Boston.
→ After nabbing an ok from the FDA for their beta-thalassemia drug Reblozyl with their partner Celgene to treat anemia in adults who require regular transfusions, Acceleron‘s EVP and CBO John Quisel is hitting the exit. Quisel is heading to helm a venture-backed startup biotech company as CEO, though Acceleron isn’t saying which company that is. Quisel joined Acceleron in 2006.
→ Vivek Ramaswamy‘s Roivant Sciences subsidiary Dermavant has named Chris Chapman as CCO. Chapman joined the dermatology-focused company after his recent stint as VP and general manager, US prescription business for Galderma. Prior to his time at Galderma, Chapman served in roles at Pfizer, Medicis Pharmaceutical and consulting firm The Core Access Group.
→ Santhera Pharmaceuticals — who, back in August, boasted positive Phase IIa data for their alternative steroid vamorolone — has brought on Andrew Smith as CFO. Most recently, Smith served as the CFO and COO of Allecra Therapeutics. Prior to that, he did a stint as CFO at Sucampo Pharmaceuticals.
→ CBD Emporium — a retailer of cannabidiol products — has snagged Paul Steinberg as COO. Steinberg’s previous stints include roles at Abraxis Bioscience (acquired by Celgene), PPD, Novella Clinical (a Quintiles company) and Simbec-Orion.
→ Summit Therapeutics — focused on the development of antibiotics — has announced that its COO, CMO and president of R&D, David Roblin, is resigning. Roblin joined the company in early 2017.
→ Cancer-focused Avacta Group has welcomed GSK vet Paul Fry as non-executive director. Fry hopped over to the company after serving as interim CEO at Vectura Group as well as CFO of the company. Previously, Fry held roles at Immunocore and Vodafone.
→ The former president and COO of Sarepta Therapeutics, Alan Timmins, has hopped aboard CytoDyn — currently developing a CCR5 antagonist, leronlimab (PRO 140) — as a member of the board of directors as an independent director and chair of the board’s audit committee.
→ BeyondSpring, a cancer-focused biotech with deep roots in China, has brought on Roche vet Daniel Zabrowski and the company’s CMO and EVP, R&D Ramon Mahanlal to its board of directors.
→ Astellas Pharma’s US president Percival Barretto-Ko has joined the board of directors, for a three-year long term, of health-focused relief and development organization Americares.